UBS Group Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price lowered by UBS Group from $35.00 to $27.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Several other analysts have also weighed in on XRAY. StockNews.com lowered shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. Evercore ISI dropped their price objective on shares of DENTSPLY SIRONA from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Needham & Company LLC decreased their target price on DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Robert W. Baird dropped their price target on DENTSPLY SIRONA from $31.00 to $24.00 and set a “neutral” rating on the stock in a research report on Friday, November 8th. Finally, Leerink Partnrs lowered DENTSPLY SIRONA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.40.

DENTSPLY SIRONA Price Performance

XRAY opened at $19.31 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.84 and a current ratio of 1.25. DENTSPLY SIRONA has a 1-year low of $17.21 and a 1-year high of $37.60. The company has a 50-day moving average of $22.02 and a 200-day moving average of $24.55. The company has a market capitalization of $3.84 billion, a P/E ratio of -9.33, a PEG ratio of 1.90 and a beta of 0.96.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.02. The firm had revenue of $951.00 million for the quarter, compared to analysts’ expectations of $939.10 million. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. DENTSPLY SIRONA’s revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.49 earnings per share. Equities analysts expect that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Large investors have recently bought and sold shares of the stock. Scientech Research LLC bought a new position in DENTSPLY SIRONA during the second quarter valued at about $846,000. VELA Investment Management LLC acquired a new position in shares of DENTSPLY SIRONA in the 3rd quarter worth approximately $2,168,000. M&G Plc acquired a new stake in DENTSPLY SIRONA during the second quarter valued at approximately $8,817,000. Empowered Funds LLC bought a new stake in DENTSPLY SIRONA during the third quarter worth approximately $2,468,000. Finally, Country Club Bank acquired a new position in DENTSPLY SIRONA in the third quarter worth approximately $4,084,000. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.